건강보험심사청구 자료에 근거한 병용금기 약물의 후향적 약물사용평가 : 처방전 조제 형태별 분석

Retrospective Drug Utilization Review of Drug-Drug Interaction Criteria Based on Real World Data: Analysis in Terms of Dispensing Types

  • 이영숙 (원광대학교 약학대학 약품연구소) ;
  • 신현택 (숙명여자대학교 약학대학)
  • Lee, Young-Sook (College of Pharmacy, Institute of Pharmaceutical Research and Development, Wonkwang University) ;
  • Shin, Hyun-Taek (College of Pharmacy, Sookmyung Women's University)
  • 투고 : 2011.07.01
  • 심사 : 2011.08.17
  • 발행 : 2011.09.30

초록

Objective: To examine the drug use (prescribing) pattern of serious drug-drug interactions (DDIs, contraindicated drug interactions) using real world data. Prescription patterns were examined in terms of dispensing types. Method: Retrospective drug utilization review (DUR) study was performed. One hundred and six datasets of serious DDIs (DDI pairs) were determined among DDI datasets that Ministry of Health & Welfare announced for the DUR system from 2004 to 2005. Electronically transacted ambulatory patients' prescription database to Health Insurance Assessment and Review Services (HIRA) from July, 2005 to June, 2006 was collected with personal information deidentified and analyzed in terms of types of dispensing as a contributing factor. Results: After prescription data analysis per each patient, total number of DDI cases using 95 DDI pairs was 5,511, which accounted for 2.6 cases per patients. DDI cases between two drugs from each of community pharmacy dispensing- type prescription were considerable (63% vs. 24% in those from each of in-institutional dispensing-type prescription and vs. 13% in those from a community pharmacy dispensing-type prescription and an in-institutional dispensingtype prescription). Conclusions: DDI cases from different prescribers were found to be significant. Thus, the concurrent DUR process between prescriptions from different physicians and institutions should be implemented for the safe drug use.

키워드

참고문헌

  1. Lazarou J, Pomeranz BH, Corey PN. Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies. JAMA 1998; 279: 1200-1205. https://doi.org/10.1001/jama.279.15.1200
  2. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. .Arch Intern Med. 1995; 155: 1949-1956. https://doi.org/10.1001/archinte.1995.00430180043006
  3. Pirmohamed M, James S, Meakin S, et al., Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19. https://doi.org/10.1136/bmj.329.7456.15
  4. 식품의약품안전청 보도자료. "식약청, 의약품 적정사용 정보 지원 방안 발표". 식품의약품안전청 의약품관리팀. 자료등록일 2006.1.31. www.kfda.go.kr (accessed on Sep 5, 2011).
  5. 보건복지부 보도자료. "의약품처방조제지원시스템(DUR) 시범사업 제주도로 확대 실시" 보건복지부 의약품정책과. 자료등록일 2009.10.30., www.mw.go.kr (accessed on Sep 5, 2011).
  6. 약업신문 기사. "약국가 병용금기 처방 조제시 삭감 주의"- 약제비청구명세서에 DUR확인사항 기재해야. 기인호 기자. 기사게재일 2006-04-27. www.yakup.com. (accessed on Sep 5, 2011)
  7. 의약뉴스 기사. "처방권 침해 VS 약품비 절감 평가 갈려". 기사게재일 2010.5.28. www.newsmp.com (accessed on Sep 5, 2011)
  8. "요양급여의 적용기준 및 방법에 관한 세부사항(약제)" 개정 고시. 보건복지부 고시 제2004-2호, 고시일 2004.1.16. 건강보험심사평가원. www.hira.or.kr (accessed on Sep 5, 2011).
  9. "요양급여의 적용기준 및 방법에 관한 세부사항(약제)" 개정 고시. 보건복지부 고시 제2005-17호, 고시일 2005.3.9. 건강보험심사평가원. www.hira.or.kr (accessed on Sep 5, 2011)
  10. "병용금기" 및 "특정 연령대 사용금기" 의약품 공고 제 2007-68호. 식품의약품안전청. 의약품관리팀. 공고일 2007.4.11. 식품의약품안전청. www.kfda.go.kr (accessed on Sep 5, 2011)
  11. 2007년 4월 "심평원 약가파일, 약제 급여 목록 및 급여 상한금액표" 개정 고시, 보건복지부 고시 제2007-24호. 공포일 2007.3.21, 시행일 2007.4.1. 건강보험심사평가원 약제등재부. www.hira.or.kr (accessed on Sep 5, 2011)
  12. 데일리팜 기사. "병용/연령금기 처방 여전...4월현재 7815건". 강신국 기자. 기사게재일 2007-09-06. www.dreamdrug.com. (accessed on Sep 5, 2011)